Dr. Lawrence Leichman, Director of the Aptium Oncology GI Cancer Consortium (AGICC), presented two posters at the ASCO-NCI-EORTC Annual Meeting held in Hollywood, Florida October 17-18, 2010.
The posters are the first publications from the AGICC trials. The first poster, titled ‘DNA Repair and Apoptosis,’ was authored by Dr. Leichman and members of the Consortium. The second poster pertains to a Phase II study of a combination compound for advanced colorectal cancer.
AGICC provides expertise and innovative solutions for the rapid start-up and completion of complex GI cancer trials. It includes a consortium of world-class investigators and institutions committed to advancing clinical and translational research in gastrointestinal malignancies. It focuses on GI-specific cancers in Phase I, Phase IB and Phase II clinical trials.
CLICK HERE to view the poster: DNA Repair and Apoptosis
A phase II trial to assess the single-agent efficacy and safety of the PARP inhibitor olaparib (O) in previously treated patients with metastatic, measurable colorectal cancer (mCRC) stratified by microsatellite status (MSs).
CLICK HERE to view the poster: A Dose-Finding and Phase II Study of selumetinib (Hyd-Sulfate), AZD6244, in Combination with Irinotecan as 2nd Line Therapy in Patients with KRAS or BRAF Mutation Positive Advanced Colorectal Cancer
About AGICC and AMyC
The Aptium Oncology GI Cancer Consortium and Aptium Oncology Myeloma Consortium provide expertise and innovative solutions for the rapid start-up and completion of complex cancer trials with translational endpoints. These consortia bring together the highest quality institutions and pharmaceutical sponsors to use the best possible data in the fastest way possible, to facilitate and speed the decision-making process in drug development.